Last reviewed · How we verify
FOLFOX , FOLFIRI or FOLFOXIRI regimens
FOLFOX , FOLFIRI or FOLFOXIRI regimens is a Small molecule drug developed by Nanfang Hospital, Southern Medical University. It is currently in Phase 1 development. Also known as: oxaliplatin, irinotecan, 5-fluorouracil.
At a glance
| Generic name | FOLFOX , FOLFIRI or FOLFOXIRI regimens |
|---|---|
| Also known as | oxaliplatin, irinotecan, 5-fluorouracil |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy (PHASE3)
- RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (NA)
- Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer (NA)
- Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma (PHASE2)
- Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX , FOLFIRI or FOLFOXIRI regimens CI brief — competitive landscape report
- FOLFOX , FOLFIRI or FOLFOXIRI regimens updates RSS · CI watch RSS
- Nanfang Hospital, Southern Medical University portfolio CI
Frequently asked questions about FOLFOX , FOLFIRI or FOLFOXIRI regimens
What is FOLFOX , FOLFIRI or FOLFOXIRI regimens?
FOLFOX , FOLFIRI or FOLFOXIRI regimens is a Small molecule drug developed by Nanfang Hospital, Southern Medical University.
Who makes FOLFOX , FOLFIRI or FOLFOXIRI regimens?
FOLFOX , FOLFIRI or FOLFOXIRI regimens is developed by Nanfang Hospital, Southern Medical University (see full Nanfang Hospital, Southern Medical University pipeline at /company/nanfang-hospital-southern-medical-university).
Is FOLFOX , FOLFIRI or FOLFOXIRI regimens also known as anything else?
FOLFOX , FOLFIRI or FOLFOXIRI regimens is also known as oxaliplatin, irinotecan, 5-fluorouracil.
What development phase is FOLFOX , FOLFIRI or FOLFOXIRI regimens in?
FOLFOX , FOLFIRI or FOLFOXIRI regimens is in Phase 1.
Related
- Manufacturer: Nanfang Hospital, Southern Medical University — full pipeline
- Also known as: oxaliplatin, irinotecan, 5-fluorouracil
- Compare: FOLFOX , FOLFIRI or FOLFOXIRI regimens vs similar drugs
- Pricing: FOLFOX , FOLFIRI or FOLFOXIRI regimens cost, discount & access